Microarray patches for managing infections at a global scale

Qonita Kurnia Anjani, Akmal Hidayat Bin Sabri, Aaron J. Hutton, Álvaro Cárcamo-Martínez, Luki Ahmadi Hari Wardoyo, Alvanov Zpalanzani Mansoor, Ryan F. Donnelly

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Since the first patent for micro array patches (MAPs) was filed in the 1970s, research on utilising MAPs as a drug
delivery system has progressed significantly, evidenced by the transition from the simple ‘poke and patch’ of
solid MAPs to the development of bio responsive systems such as hydrogel-forming and dissolving MAPs. In
addition to the extensive research on MAPs for improving transdermal drug delivery, there is a growing interest
in using these devices to manage infectious diseases. This is due to the minimally invasive nature of this drug
delivery platform which enable patients to self-administer therapeutics without the aid of healthcare professionals. This review aims to provide a critical analysis on the potential utility of MAPs in managing infectious
diseases which are still endemic at a global scale. The range of diseases covered in this review include tuberculosis, skin infections, malaria, methicillin-resistant Staphylococcus aureus infections and Covid-19. These diseases exert a considerable socioeconomic burden at a global scale with their impact magnified in low- and
middle-income countries (LMICs). Due to the painless and minimally invasive nature of MAPs application,
this technology also provides an efficient solution not only for the delivery of therapeutics but also for the
administration of vaccine and prophylactic agents that could be used in preventing the spread and outbreak of
emerging infections. Furthermore, the ability of MAPs to sample and collect dermal interstitial fluid that is rich in
disease-related biomarkers could also open the avenue for MAPs to be utilised as a minimally invasive biosensor
for the diagnosis of infectious diseases. The efficacy of MAPs along with the current limitations of such strategies
to prevent and treat these infections will be discussed. Lastly, the clinical and translational hurdles associated
with MAP technologies will also be critically discussed.
Original languageEnglish
Pages (from-to)97-115
Number of pages19
JournalJournal of Controlled Release
Early online date2 Jun 2023
Publication statusPublished online - 2 Jun 2023

Data Access Statement

Data will be made available on request.


  • Microarray patch
  • Infectious disease
  • Tuberculosis
  • Skin infection
  • Malaria
  • MRSA
  • Covid-19


Dive into the research topics of 'Microarray patches for managing infections at a global scale'. Together they form a unique fingerprint.

Cite this